Irina Shapiro
Vice President - Translational Research Cullinan Therapeutics
Cancer biologist with 10+ years of translational research, oncology and immune oncology drug development experience. Strong expertise in mechanism of action studies, biomarker discovery and validation, characterization of anti-tumor immune responses using immunohistochemistry, multiplex immunofluorescence, genomic and proteomic analysis. Translational biomarker strategy development and implementation in immune oncology clinical trials (Phase I POC to Phase III/BLA submission).
Seminars
Advancing Diagnostics & Biomarkers to Definitively Characterize the B-Cell Repertoire & Success of Immune Resetting Therapeutics in a Clinical Setting
Join this workshop to explore how immune resetting is being measured in the clinic:
- Highlighting the disconnect between B-cell levels in peripheral blood and their persistence in the lymph nodes following conventional antibody therapies
- Discussing the necessity of lymph node biopsies as a direct, ex vivo method to accurately quantify the depth of depletion to address the disruption of the follicular pathway in the lymph nodes to provide a measure of therapeutic effects
- Comparing the tissue outcomes across different therapeutic modalities linking deep lymphoid tissue depletion to the potential for sustained, long-term remission
- Effectively analyzing the B-cell repertoire to gain insights into effectiveness of the treatment after resetting the immune system
- Utilizing B-cell receptor gene sequencing to precisely track and confirm the deep and sustained elimination of these initial pathogenic B-cells following immuneresetting therapy
- Ensuring newly generated B-cells are free of the original pathogenic B-cells as molecular evidence for the restoration of self-tolerance
- Establishing molecular signatures that predict long-term remission
